$0.35
(0.99%)
Add to watchlist
Create an alert
Stocks and Shares ISANewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Company Information
About this company
Key people
Michael Harvey Davidson
Chief Executive Officer, Executive Director
Louise Kooij
Interim Chief Financial Officer
Douglas Kling
Chief Operating Officer
John Kastelein
Chief Scientific Officer, Non-Executive Director
Juliette Audet
Chief Business Officer
Marc Ditmarsch
Chief Development Officer
William H. Lewis
Independent Chairman of the Board
Nicholas Downing
Director
Janneke Van Der Kamp
Temporary Non-Executive Director
Adele M. Gulfo
Independent Director
Wouter Joustra
Independent Director
Click to see more
Key facts
- Shares in issue113.39m
- EPICNAMS
- ISINNL00150012L7
- LocationNetherlands
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$4.02bn
- Employees77
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.